Business Combinations - Additional Information (Details) $ / shares in Units, $ in Thousands				1 Months Ended	12 Months Ended
	Aug. 31, 2022 USD ($)	Jul. 25, 2022 USD ($) plan $ / shares shares	Sep. 01, 2021 USD ($) trading_day d $ / shares shares	Aug. 31, 2021 shares	Dec. 31, 2022 USD ($) $ / shares	Dec. 31, 2021 USD ($) $ / shares	Aug. 25, 2022 USD ($)
Schedule of Reverse Recapitalization [Line Items]
Consideration payable			$ 1,250,000
Cash paid to shareholders			$ 50,000
Common stock, par value (in dollars per share) | $ / shares			$ 0.0001		$ 0.0001	$ 0.0001
Earn-out shares, stock price trigger (in dollars per share) | $ / shares			$ 20.00
Earnout period, threshold trading days | d			20
Earnout period, threshold consecutive trading days | trading_day			30
Common stock issued pursuant to the PIPE Investment (in shares) | shares			36,500,000
Purchase price (in dollars per share) | $ / shares			$ 10.00
Proceeds from reverse recapitalization, gross			$ 365,000
Gross proceeds			619,400
Proceeds from CMLS II, gross			254,400
Reverse recapitalization, cash paid to shareholders, cash election related to issuance and rollover of shares			50,000
CMLS II and reverse recapitalization transaction costs			$ 39,300
Number of potential payments | plan		3
Total revenue					$ 97,666	$ 81,626
Expenses					273,427	154,930
Share-based payment arrangement, expense					43,609	28,415
Accrued lease termination fee					2,500	0	$ 2,500
Acquisition, transaction costs						$ 35,111
CMLS II
Schedule of Reverse Recapitalization [Line Items]
Redemption of shares (in shares) | shares			809,850
Stock price (in dollars per share) | $ / shares			$ 10.00
Stock redeemed, value			$ 8,100
Stock converted from reverse capitalization (in shares) | shares			6,900,000
Stock converted, reverse recapitalization, conversion basis			100.00%
Class A Common Stock
Schedule of Reverse Recapitalization [Line Items]
Exchange ratio			0.8381
Common stock, par value (in dollars per share) | $ / shares			$ 0.0001
Common Stock
Schedule of Reverse Recapitalization [Line Items]
Common stock issued, price per share (in dollars per share) | $ / shares			$ 10.00
Stock converted from reverse capitalization (in shares) | shares			110,973,213	12,342
Old SomaLogic Shareholders
Schedule of Reverse Recapitalization [Line Items]
Earn-out shares, additional shares (in shares) | shares			3,500,125
Certain Employees and Directors
Schedule of Reverse Recapitalization [Line Items]
Earn-out shares, additional shares (in shares) | shares			1,499,875
Palamedrix, Inc
Schedule of Reverse Recapitalization [Line Items]
Percentage of voting interest acquired		100.00%
Total revenue					0
Expenses					2,100
Common stock, shares issued (in shares) | shares		3,215,295
Share price (in dollars per share) | $ / shares		$ 3.68
Consideration transferred, post-combination compensation expense	$ 1,300
Acquisition, transaction costs					3,700
Palamedrix, Inc | Palamedrix Employees
Schedule of Reverse Recapitalization [Line Items]
Common stock, shares issued (in shares) | shares		815,177
Palamedrix, Inc | Founder
Schedule of Reverse Recapitalization [Line Items]
Share-based payment arrangement, expense					600
Award requisite service period	3 years
Palamedrix, Inc | Founder | Milestone Contingent Consideration
Schedule of Reverse Recapitalization [Line Items]
Vesting period	3 years
Palamedrix, Inc | Milestone Contingent Consideration
Schedule of Reverse Recapitalization [Line Items]
Contingent consideration, range of outcomes, high		$ 17,500
Contingent consideration liability					$ 1,300
Palamedrix, Inc | Pre-Acquisition Legal Matters
Schedule of Reverse Recapitalization [Line Items]
Contingent consideration, range of outcomes, high		$ 500